XML 78 R61.htm IDEA: XBRL DOCUMENT
v3.25.3

Investment in Cyclo Therapeutics, Llc. (Details) - USD ($) |  |  |  |  |  |  |  | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 23, 2024 | Oct. 20, 2023 | Aug. 01, 2023 | May 02, 2023 | Feb. 09, 2023 | Nov. 15, 2021 | Feb. 03, 2020 | Jul. 31, 2025 | Jul. 31, 2024 | Mar. 25, 2025 | Sep. 01, 2021 | Mar. 31, 2021
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Realized gain (in Dollars) |  |  |  |  |  |  |  | $ 178,000 | $ 1,772,000 |  |  |
Outstanding principal and accrued interest (in Dollars) | $ 2,500,000 |  |  |  |  |  |  | $ 30,600,000 |  |  |  |
Cyclo common stock (in Shares) | 3,968,254 |  |  |  |  |  |  |  |  | 12,998,194 |  |
Unrealized gains (in Dollars) |  |  |  |  |  |  |  |  | $ 37,000 |  |  |
Percentage of issued and outstanding shares |  |  |  |  |  |  | 12.00% |  |  |  |  |
Price per share (in Dollars per share) |  |  |  |  |  |  |  | $ 0.005 |  | $ 0.72 |  |
Ownership interests |  |  |  |  |  |  |  | 37.50% |  |  |  |
Line of Credit Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Amount of revolving commitment to funds (in Dollars) |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares (in Shares) |  |  | 4,000,000 | 2,514,970 |  |  |  |  |  |  |  |
Purchase of warrants (in Shares) |  | 2,514,970 | 4,000,000 | 2,514,970 |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  | $ 0.71 | $ 1.25 | $ 0.71 |  |  |  |  |  |  |  |
Aggregate purchase price (in Dollars) |  |  | $ 5,000,000 | $ 2,100,000 |  |  |  |  |  |  |  |
Unrealized loss (in Dollars) |  |  |  |  |  |  |  | $ 5,100,000 |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] | May Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  |  |  | $ 0.835 |  |  |  |  |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] | Replacement Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Purchase of warrants (in Shares) |  | 2,766,467 |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) |  | $ 0.95 |  |  |  |  |  |  |  |  |  |
Investment in Cyclo Therapeutics, Inc. [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  | 49.00% |  |  |  |  |  |  |  |  |  |
Realized gain (in Dollars) |  | $ 424,000 |  |  |  |  |  |  |  |  |  |
Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Receivable balance due (in Dollars) |  |  |  |  |  |  |  | $ 720,000 |  |  |  |
Percentage of issued and outstanding shares |  |  |  |  |  |  |  | 12.00% |  |  |  |
Diluted capital stock |  |  |  |  |  |  |  | 10.00% |  |  |  |
Fully diluted capital stock |  |  |  |  |  |  |  | 10.00% |  |  |  |
Percentage of issued and outstanding equity |  |  |  |  |  |  |  | 51.00% |  |  |  |
Cornerstone [Member] | Line of Credit Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Loan from line of credit agreement (in Dollars) |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |
Payment to fund RP finance line of credit (in Dollars) |  |  |  |  |  |  |  | $ 21,900,000 |  |  |  |
Lipomedix Pharmaceuticals Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Financing principal amount (in Dollars) |  |  |  |  |  |  |  |  |  |  |  | $ 400,000
Purchase of ordinary shares (in Shares) |  |  |  |  | 70,000,000 | 15,975,000 |  | 15,975,000 |  |  |  |
Price per share (in Dollars per share) |  |  |  |  | $ 0.03 |  |  |  |  |  |  |
Purchase price (in Dollars) |  |  |  |  | $ 2,100,000 | $ 3,000,000 |  | $ 3,000,000 |  |  |  |
Principal amount outstanding (in Dollars) |  |  |  |  |  |  |  |  |  |  |  | 400,000
Accrued interest (in Dollars) |  |  |  |  |  |  |  |  |  |  |  | $ 21,800
Cash payment (in Dollars) |  |  |  |  |  |  |  | $ 2,600,000 |  |  |  |
Investment owned percentage |  |  |  |  | 95.00% |  |  | 84.00% |  |  |  |
Noncontrolling interest (in Dollars) |  |  |  |  | $ 16,000 |  |  | $ 8,000 |  |  |  |
Lipomedix Pharmaceuticals Ltd. [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Purchase of ordinary shares (in Shares) |  |  |  |  |  | 15,975,000 |  |  |  |  |  |
Price per share (in Dollars per share) |  |  |  |  |  | $ 0.1878 |  |  |  |  |  |
RP Finance, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 37.50% |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) |  |  |  |  |  |  |  | 6,067,306 |  |  |  |
Other Stockholders [Member] | RP Finance, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |
Share Purchase Agreement [Member] | Lipomedix Pharmaceuticals Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment owned percentage |  |  |  |  | 5.00% |  |  |  |  |  |  |
Rafael Holdings Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership shares increased (in Shares) | 12,998,194 |  |  |  |  |  |  | 12,998,194 |  |  |  |
Rafael Holdings Inc [Member] | Investment in Cyclo Therapeutics, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage | 39.50% |  |  |  |  |  |  |  |  |  |  |
Rafael Holdings Inc [Member] | Lipomedix Pharmaceuticals Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Noncontrolling interest percentage |  |  |  |  |  |  |  | 16.00% |  |  |  |
Loan [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Accrued interest (in Dollars) |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |
2023 Promissory Note [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Cumulative total (in Dollars) |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Interest rate |  |  |  |  |  |  |  | 7.50% |  |  |  |
RPF Line of Credit [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 37.50% |  |  |  |
Amount of revolving commitment to funds (in Dollars) |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |
Percentage of funding request required |  |  |  |  |  |  |  | 37.50% |  |  |  |
Post-Reverse Stock Split [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Stock split (in Shares) |  |  |  |  |  |  |  | 261,230 |  |  |  |
Post-Reverse Stock Split [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) |  |  |  |  |  |  | 261,230 |  |  |  |  |
Investment, Identifier [Axis]: Lipomedix Pharmaceuticals Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  | Nov. 11, 2022 |  |  |  |  | Sep. 01, 2021 | Sep. 01, 2021
Interest rate |  |  |  |  |  |  |  |  |  |  | 15.00% | 8.00%
Pharma Holdings [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 50.00% |  |  |  |
Percentage of owned non-operating subsidiary |  |  |  |  |  |  |  | 90.00% |  |  |  |
Percentage of owned subsidiary |  |  |  |  |  |  |  | 43.00% |  |  |  |
Pharma Holdings [Member] | Rafael Holdings Inc [Member] | Cornerstone [Member] | Howard Jonas [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 10.00% |  |  |  |
CS Pharma Holdings [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 90.00% |  |  |  |
Percentage of owned non-operating subsidiary |  |  |  |  |  |  |  | 50.00% |  |  |  |
Indirect interest |  |  |  |  |  |  |  | 45.00% |  |  |  |
Percentage of issued and outstanding equity |  |  |  |  |  |  |  | 8.00% |  |  |  |
Minimum [Member] | RPF Line of Credit [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Cumulative total (in Dollars) |  |  |  |  |  |  |  | $ 21,900,000 |  |  |  |
Maximum [Member] | RPF Line of Credit [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Cumulative total (in Dollars) |  |  |  |  |  |  |  | $ 9,375,000 |  |  |  |
Series D Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) |  |  |  |  |  |  |  | 60,673,087 |  |  |  |
Series D Preferred Stock [Member] | Pharma Holdings [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock (in Dollars) |  |  |  |  |  |  |  | $ 44,000,000 |  |  |  |
Series D Preferred Stock [Member] | CS Pharma Holdings [Member] | Cornerstone [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment In Cyclo Therapeutics, LLC [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock (in Dollars) |  |  |  |  |  |  |  | $ 16,700,000 |  |  |  |

X
- Definition Accrued interest. + References No definition available. + Details
Name: | rfl_AccruedInterest
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payment. + References No definition available. + Details
Name: | rfl_CashPayment
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of fully diluted basis. + References No definition available. + Details
Name: | rfl_FullyDilutedBasisPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of fully diluted capital stock. + References No definition available. + Details
Name: | rfl_FullyDilutedCapitalStock
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rfl_IndirectInterestAssetsPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Outstanding principal and accrued interest. + References No definition available. + Details
Name: | rfl_OutstandingPrincipalAndAccruedInterest
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Ownership interest percentage. + References No definition available. + Details
Name: | rfl_OwnershipInterestPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ownership interests. + References No definition available. + Details
Name: | rfl_OwnershipInterests
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of payment to fund rp finance line of credit. + References No definition available. + Details
Name: | rfl_PaymentToFundRPFinanceLineOfCredit
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. + References No definition available. + Details
Name: | rfl_PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding request required. + References No definition available. + Details
Name: | rfl_PercentageOfFundingRequestRequired
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of issued and outstanding equity. + References No definition available. + Details
Name: | rfl_PercentageOfIssuedAndOutstandingEquity
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of issued and outstanding shares of common stock. + References No definition available. + Details
Name: | rfl_PercentageOfIssuedAndOutstandingShare
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of receivable balance due. + References No definition available. + Details
Name: | rfl_ReceivableBalanceDue
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of unrealized gain in equity investments. + References No definition available. + Details
Name: | rfl_UnrealizedGainInEquityInvestmentsCycloTherapeuticsInc
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of unrealized loss in equity investments. + References No definition available. + Details
Name: | rfl_UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Increase for accrued, but unpaid interest on the debt instrument for the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentIncreaseAccruedInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details
Name: | us-gaap_DebtSecuritiesRealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Rate of interest on investment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Maturity date of investment, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of principal of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalancePrincipalAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of investment owned to net assets. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedPercentOfNetAssets
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_LineOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (01)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_PreferredStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This is the principal amount outstanding for loans which are in the process of being securitized as of the date of the statement of financial position (across all types of loans). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (a) -Paragraph 4 -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4 + Details
Name: | us-gaap_PrincipalAmountOutstandingOnLoansHeldForSaleOrSecuritization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of noncontrolling interests which are redeemable by the parent entity, classified as other equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (24) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A + Details
Name: | us-gaap_RedeemableNoncontrollingInterestEquityOtherCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 40 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480520/718-40-45-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reduction in the number of shares during the period as a result of a reverse stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of a stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478297/946-220-50-3 + Details
Name: | us-gaap_SummaryOfInvestmentHoldingsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_InvestmentInCycloTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=rfl_MayWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=rfl_ReplacementWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_CornerstoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_LipomedixPharmaceuticalsLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_RPFinanceLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=rfl_OtherStockholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rfl_SharePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_RafaelHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_LoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_TwoThousandTwentyThreePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_RPFLineOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=rfl_PostReverseStockSplitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentIdentifierAxis=Lipomedix Pharmaceuticals Ltd. [Member]
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rfl_PharmaHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rfl_HowardJonasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rfl_CSPharmaHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |